Alteration of the spontaneous systemic autoimmune disease in (NZB × NZW)F1 mice by treatment with thimerosal (ethyl mercury)

Toxicology and Applied Pharmacology

Volumn 214, Issue 1, 2006, Pages 43-54

  Havarinasab, S ^a   Hultman, P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

(NZB NZW)F1 mice; Autoimmunity; Immune complex; Mice; Thimerosal

Indexed keywords

ANTINUCLEAR ANTIBODY; DRINKING WATER; HYDROGEN SULFIDE; MERCURY CHLORIDE; THIOMERSAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; BLOOD VESSEL WALL; BODY WEIGHT; CAPILLARY WALL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GLOMERULONEPHRITIS; IMMUNE COMPLEX DEPOSITION; IMMUNE COMPLEX NEPHRITIS; KIDNEY BLOOD VESSEL; KIDNEY INJURY; LOW DRUG DOSE; MESANGIUM; MORTALITY; MOUSE; NONHUMAN; PROTEINURIA;

MURINAE;

EID: 33744991787     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.12.004     Document Type: Article

References (47)

1. Abedi-Valugerdi M., Hu H., and Moller G. Mercury-induced renal immune complex deposits in young (NZB × NZW)F1 mice: characterization of antibodies/autoantibodies. Clin. Exp. Immunol. 110 (1997) 86-91
2. al-Balaghi S., Moller E., Moller G., and Abedi-Valugerdi M. Mercury induces polyclonal B cell activation, autoantibody production and renal immune complex deposits in young (NZB × NZW)F1 hybrids. Eur. J. Immunol. 26 (1996) 1519-1526
3. Ball L.K., Ball R., and Pratt R.D. An assessment of thimerosal use in childhood vaccines. Pediatrics 107 (2001) 1147-1154
4. Barnes D.G., and Dourson M. Reference dose (RfD): description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8 (1988) 471-486
5. Bigham M., and Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf. 28 (2005) 89-101
6. Border W.A., Ward H.J., Kamil E.S., and Cohen A.H. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J. Clin. Invest. 69 (1982) 451-461
7. Burlingame R.W., and Rubin R.L. Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J. Immunol. Methods 134 (1990) 187-199
8. Clarkson T.W. Principles of risk assessment. Adv. Dent. Res. 6 (1992) 22-27
9. Clarkson T.W. The three modern faces of mercury. Environ. Health Perspect. 110 Suppl. 1 (2002) 11-23
10. Counter S.A., and Buchanan L.H. Mercury exposure in children: a review. Toxicol. Appl. Pharmacol. 198 (2004) 209-230
11. Descotes J. Immunotoxicology of drugs and chemicals. Elsevier (1986) 296-381
12. Dourson M.L., Wullenweber A.E., and Poirier K.A. Uncertainties in the reference dose for methylmercury. Neurotoxicology 22 (2001) 677-689
13. Enestrom S., and Hultman P. Immune-mediated glomerulonephritis induced by mercuric chloride in mice. Experientia 40 (1984) 1234-1240
14. Gauthier V.J., Mannik M., and Striker G.E. Effect of cationized antibodies in performed immune complexes on deposition and persistence in renal glomeruli. J. Exp. Med. 156 (1982) 766-777
15. Germuth F.G., Rodriguez E., Lorelle C.A., Trump E.I., Milano L., and Wise O. Passive immune complex glomerulonephritis in mice: models for various lesions found in human disease. I. High avidity complexes and mesangiopathic glomerulonephritis. Lab. Invest. 41 (1979) 360-365
16. Haggqvist B., Havarinasab S., Bjorn E., and Hultman P. The immunosuppressive effect of methylmercury does not preclude development of autoimmunity in genetically susceptible mice. Toxicology 208 (2005) 149-164
17. Harry G.J., Harris M.W., and Burka L.T. Mercury concentrations in brain and kidney following ethylmercury, methylmercury and thimerosal administration to neonatal mice. Toxicol. Lett. 154 (2004) 183-189
18. Havarinasab S., Lambertsson L., Qvarnstrom J., and Hultman P. Dose-response study of thimerosal-induced murine systemic autoimmunity. Toxicol. Appl. Pharmacol. 194 (2004) 169-179
19. Havarinasab S., Haggqvist B., Bjorn E., Pollard K.M., and Hultman P. Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol. Appl. Pharmacol. 204 (2005) 109-121
20. Hultman P., and Enestrom S. Mercury induced antinuclear antibodies in mice: characterization and correlation with renal immune complex deposits. Clin. Exp. Immunol. 71 (1988) 269-274
21. Hultman P., and Enestrom S. Dose-response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicol. Appl. Pharmacol. 113 (1992) 199-208
22. Hultman P., and Nielsen J.B. The effect of dose, gender, and non-H-2 genes in murine mercury-induced autoimmunity. J. Autoimmun. 17 (2001) 27-37
23. Hultman P., Skogh T., and Enestrom S. Circulating and tissue immune complexes in mercury-treated mice. J. Clin. Lab. Immunol. 29 (1989) 175-183
24. Hultman P., Ganowiak K., Turley S.J., and Pollard K.M. Genetic susceptibility to silver-induced anti-fibrillarin autoantibodies in mice. Clin. Immunol. Immunopathol. 77 (1995) 291-297
25. Humbel R.L. Detection of Antinuclear Antibodies by Immunofluorescence (1993), Kluwer Academic Publishers, Netherlands
26. IOM. Immunization Safety Review: Vaccines and Autism (2004), National Academies Press, Washington, DC
27. Johansson U., Hansson-Georgiadis H., and Hultman P. Murine silver-induced autoimmunity: silver shares induction of antinucleolar antibodies with mercury, but causes less activation of the immune system. Int. Arch. Allergy Immunol. 113 (1997) 432-443
28. Lee-Wong M., Resnick D., and Chong K. A generalized reaction to thimerosal from an influenza vaccine. Ann. Allergy Asthma Immunol. 94 (2005) 90-94
29. Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J. Appl. Toxicol. 21 (2001) 1-5
30. Maibach H. Acute laryngeal obstruction presumed secondary to thiomersal (merthiolate) delayed hypersensitivity. Contact Dermatitis 1 (1975) 221-222
31. Nakajima A., Hirose S., Yagita H., and Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J. Immunol. 158 (1997) 1466-1472
32. Nangaku M., and Couser W.G. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. 9 (2005) 183-191
33. Parker S.K., Schwartz B., Todd J., and Pickering L.K. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114 (2004) 793-804
34. Pollard K.M., Pearson D.L., Hultman P., Hildebrandt B., and Kono D.H. Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity. Environ. Health Perspect. 107 Suppl. 5 (1999) 729-735
35. Pollard K.M., Pearson D.L., Hultman P., Deane T.N., Lindh U., and Kono D.H. Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus-prone bxsb mice. Environ. Health Perspect. 109 (2001) 27-33
36. Pollard K.M., Hultman P., and Kono D.H. Immunology and genetics of induced systemic autoimmunity. Autoimmun. Rev. 4 (2005) 282-288
37. Pratt M.D., Belsito D.V., DeLeo V.A., Fowler Jr. J.F., Fransway A.F., Miabach H.I., Marks J.G., Mathias C.G., Rietschel R.L., Sasseville D., Sherertz E.F., Storrs F.J., Taylor J.S., and Zug K. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 15 (2004) 176-183
38. Qvarnstrom J., Lambertsson L., Havarinasab S., Hultman P., and Frech W. Determination of methylmercury, ethylmercury, and inorganic mercury in mouse tissues, following administration of thimerosal, by species-specific isotope dilution GC-inductively coupled plasma-MS. Anal. Chem. 75 (2003) 4120-4124
39. Seidenari S., Giusti F., Pepe P., and Mantovani L. Contact sensitization in 1094 children undergoing patch testing over a 7-year period. Pediatr. Dermatol. 22 (2005) 1-5
40. Sontheimer R.D., and Gilliam J.N. An immunofluorescence assay for double-stranded DNA antibodies using the Crithidia luciliae kinetoplast as a double-stranded DNA substrate. J. Lab. Clin. Med. 91 (1978) 550-558
41. Stratton K., Gable A., and McCormic M.C. Thimerosal-Containing Vaccines and Neurodevelopmental Disorders (2001), Institute of Medicine, Washington, DC
42. Suneja T., and Belsito D.V. Thimerosal in the detection of clinically relevant allergic contact reactions. J. Am. Acad. Dermatol. 45 (2001) 23-27
43. Theofilopoulos A.N., and Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37 (1985) 269-390
44. Theofilopoulos A.N., Koundouris S., Kono D.H., and Lawson B.R. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3 (2001) 136-141
45. Warfvinge K., Hansson H., and Hultman P. Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose-response studies. Toxicol. Appl. Pharmacol. 132 (1995) 299-309
46. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., Fogo A.B., Ginzler E.M., Hebert L., Hill G., Hill P., Jennette J.C., Kong N.C., Lesavre P., Lockshin M., Looi L.M., Makino H., Moura L.A., and Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65 (2004) 521-530
47. Wilson C.B., and Dixon F.J. Quantitation of acute and chronic serum sickness in the rabbit. J. Exp. Med. 134 (1971) 7s-8s